
Plexus (PLXS) Stock Forecast & Price Target
Plexus (PLXS) Analyst Ratings
Bulls say
Plexus Corp demonstrated a positive financial trajectory, achieving 5% year-over-year growth in its Healthcare/Life Sciences (HCLS) segment, amounting to $1.629 billion in annual revenue, with expectations for further increases driven by multiple program ramps and improving customer demand. The Aerospace and Defense (A&D) segment is projected to experience mid-single-digit quarter-over-quarter growth, bolstered by developments in commercial air and defense, indicating alignment with the company's overall revenue growth goal of 9-12% for FY26. Additionally, excluding restructuring charges, earnings growth is expected to significantly outpace revenue growth, reflecting the efficacy of Plexus's strategic initiatives and potential for continued operational leverage.
Bears say
Plexus Corp has experienced a decline in gross margin from 10.1% to 9.9%, indicating pressure on profitability despite stable operating margins, signaling potential concerns regarding cost management. Additionally, revenue from the Aerospace and Defense segment, which constitutes 16% of total revenues, decreased by 6% year-over-year and quarter-over-quarter, reflecting a trend of weakening demand in key sectors. The company faces broader economic headwinds from a potential slowdown in global growth, alongside specific risks related to manufacturing disruptions and competitive pressures, impacting its ability to differentiate itself in a challenging market environment.
This aggregate rating is based on analysts' research of Plexus and is not a guaranteed prediction by Public.com or investment advice.
Plexus (PLXS) Analyst Forecast & Price Prediction
Start investing in Plexus (PLXS)
Order type
Buy in
Order amount
Est. shares
0 shares